Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more
Cytek Biosciences Inc - Asset Resilience Ratio
Cytek Biosciences Inc (CTKB) has an Asset Resilience Ratio of 36.98% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Cytek Biosciences Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Cytek Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $170.68 Million | 36.98% |
| Total Liquid Assets | $170.68 Million | 36.98% |
Asset Resilience Insights
- Very High Liquidity: Cytek Biosciences Inc maintains exceptional liquid asset reserves at 36.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cytek Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Cytek Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
FluroTech Ltd
OTCQB:FLURF |
Medical Devices | 0.00% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 0.50% |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
Annual Asset Resilience Ratio for Cytek Biosciences Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Cytek Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 36.98% | $170.68 Million | $461.54 Million | +1.11pp |
| 2024-12-31 | 35.86% | $179.15 Million | $499.50 Million | +16.63pp |
| 2023-12-31 | 19.24% | $95.11 Million | $494.46 Million | +10.66pp |
| 2022-12-31 | 8.58% | $44.55 Million | $519.48 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $463.31 Million | -- |